By Ben Glickman
Kronos Bio said it would cut about 83% of its workforce by the end of the year and named a new interim chief executive, as the company continues to explore strategic options.
The San Mateo, Calif., biotechnology company said Wednesday that Deborah Knobelman had been appointed president and interim CEO, effective Dec. 3.
CEO Norbert Bischofberger, who has been with the company since 2018, will step down while remaining on the board of directors.
Kronos said the workforce reduction was part of its previously announced plan to cut costs and is expected to be completed by the end of the year. The company is exploring options, including a possible business combination or divestiture of its assets.
The cuts follow a 21% workforce reduction which was announced in March. Kronos expects to incur a charge of about $3.7 million related to the reduction.
Write to Ben Glickman at ben.glickman@wsj.com
(END) Dow Jones Newswires
November 27, 2024 07:47 ET (12:47 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。